Erratum to miR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma via downregulating SPRED1
Erratum to: Ann Transl Med 2021;9:38
This article (1) titled “miR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma via downregulating SPRED1” (doi: 10.21037/atm-20-2081), unfortunately contains errors in Figure 5 and Figure S2. Two images were inadvertently misused in Figure 5D and Figure S2A. Overlapped images were found in the representative images of group “Ctrl” and “SR5” of Figure 5D. Besides, the images for group “SR5” of HepG2 invasion assay in Figure S1D and Figure S2A shared common areas. These mistakes happened during figure assembly. Since all the experiments have been repeated at least three times, these corrections do not change the description, interpretation, or the original conclusions of the manuscript. The corrected Figure 5 and Figure S2 can be found below.
Corrected Figure 5:
Corrected Figure S2:
The authors apologize for the oversight.
Click here to view the updated version of the article.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References
- Tan W, Lin Z, Chen X, et al. miR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma via downregulating SPRED1. Ann Transl Med 2021;9:38. [Crossref] [PubMed]
